| 查看: 3766 | 回复: 17 | |||||
[交流]
达比加群酯的SWOT分析项
|
|||||
|
老大让我做一个SWOT分析，这对一个没有THOMSON、没有Pharmaproject的立项工作者来说，只能空手套白狼了，暂时只想出以下几个分析项，请各位虫友补充啦。 S分析 用药方法的便利性 出血安全性得到FDA、EMA等机构的屡次肯定 曾经获得FDA下属委员会全票支持 其对卒中的预防效果明显优于华法林 有间接比较研究显示，达比加群酯的成本-效益特征与有效性特征优于利伐沙班 先后在德国和加拿大被授予Prix Galien最佳药物奖 曾经获得NICE的有条件推荐 上市后市场表现强劲，已经实现了重磅炸弹级别的销售额 W分析 出血事件—达比加群酯挥之不去的阴影 肾功能损伤与P-gp是达比加群酯在其用药过程中需要调整剂量的主要因素 RE-ALLGN失败，使得人工心脏瓣膜成为达比加群酯的禁忌症之一 价格昂贵 O分析 适应证发病率高，用药市场规模庞大 需要开发新的药物，以弥补华法林的不足 利伐沙班于ROCKET-AF试验中仅证实与华法林相比的非劣性 T分析 将面临来自阿哌沙班、利伐沙班、依度沙班的激烈竞争 [ Last edited by williamxiang on 2013-4-3 at 16:31 ] |
回复此楼» 收录本帖的淘帖专辑推荐
 研发工艺 | 泮托拉唑 |
» 猜你喜欢
国家高层次人才李兴淑教授课题组招收博士研究生
已经有39人回复
-
中国药科大学2026入学博士，药物合成和设计经验，放射化学及放射医学研究
已经有25人回复
-
药物学论文润色/翻译怎么收费?
已经有228人回复
-
己酮可可碱过氧化杂质限度
已经有2人回复
-
求助Isoeugenol质量标准
已经有0人回复
-
Gliclazide
已经有0人回复
-
塞替派/噻替哌（Thiotepa） 质量控制
已经有15人回复
-
有没有大佬可以帮忙查下Trijardy XR和Qternmet XR历年销售数据呀
已经有0人回复
-
酰胺水解求助
已经有10人回复
» 本主题相关价值贴推荐，对您同样有帮助:
- 达比加群酯在中国获批
已经有17人回复
- 达比加群酯经过碱降解后产物会是什么结构？
已经有10人回复
- 达比加群酯甲磺酸盐 颜色
已经有10人回复
» 抢金币啦！回帖就可以得到:
-
武汉纺织大学电子与电气工程学院------院长团队招聘光电、材料类博士，博士后
+1/502
-
中国科学院大学纳米科学与工程学院院长唐智勇院士团队招聘启事
+1/178
-
湖南师范大学医工交叉科研团队招收博士研究生
+1/172
-
诚征另一半
+1/165
-
限广州，征女友
+2/110
-
中科院长春光机所 招收计算材料学博士/硕士研究生（含机器学习辅助材料设计方向）
+1/81
-
广州
+1/65
-
2026年黄河科技学院纳米功能材料研究所招聘
+2/46
-
加拿大卡尔加里大学 量子通信和信息方向 硕士/博士招生
+1/46
-
中国科学院大连化学物理研究所DNL0902研究组招聘博士后和职工
+1/41
-
上海大学 力工学院 锂电池方向 博士研究生招生
+1/26
-
南科大夏海平院士-深大张平玉课题组联合招聘博士后
+1/24
-
王志博教授课题组招收硕士研究生(本招收信息长期有效)
+2/20
-
中科院深圳理工大学网络课题组招聘博后/RA/实习生
+1/16
-
南京工业大学招收2026年全日制学术博士（供热、供燃气通风与空调）
+1/13
-
上海大学昝鹏教授、军事医学研究院伯晓晨研究员/倪铭副研究员 课题组招聘博士生
+2/10
-
天津大学化学系吴立朋课题组申请考核制博士招生/博后招聘
+1/6
-
天津大学化学系吴立朋课题组申请考核制博士招生/博后招聘-有机化学，金属有机
+1/5
-
求博导收留
+1/4
-
福州大学梁宇航副教授招收2026年申核制博士研究生/硕士研究生（理论计算方向）
+1/3
★ ★ ★ ★ ★ ★ ★ ★
小木虫: 金币+0.5, 给个红包，谢谢回帖
痴夷子皮: 金币+2, 谢谢交流，欢迎常来哦。 2013-04-07 08:32:30
williamxiang: 金币+5 2013-04-07 09:53:30
小木虫: 金币+0.5, 给个红包，谢谢回帖
痴夷子皮: 金币+2, 谢谢交流，欢迎常来哦。 2013-04-07 08:32:30
williamxiang: 金币+5 2013-04-07 09:53:30
|
楼上的就是来自TP中达比加群酯的SWOT分析。 给楼主个站内链接：http://muchong.com/bbs/viewthread.php?tid=5319066 建议：做产品SWOT分析的时候可结合国内情况，行业情况及本公司情况三级，给出相应的分析。 楼主对这个产品所述的SWOT分析，已相当专业了！除了专业方面的应该还有些上述建议的其他的。 个人意见，仅供参考！ |
9楼2013-04-04 00:12:48
★ ★ ★
小木虫: 金币+0.5, 给个红包，谢谢回帖
痴夷子皮: 金币+2, 谢谢交流，欢迎常来哦。 2013-04-07 08:32:18
小木虫: 金币+0.5, 给个红包，谢谢回帖
痴夷子皮: 金币+2, 谢谢交流，欢迎常来哦。 2013-04-07 08:32:18
|
Strengths The first novel anticoagulant to secure approval for stroke prevention in atrial fibrillation (AF), entering the US market in November 2010 No requirement for anticoagulation monitoring and dose adjustment, and no food effect In the RE-LY trial in AF, Pradaxa showed comparable to superior efficacy in stroke prevention, compared with warfarin, with equal to lower bleeding risk A subgroup analysis from RE-LY showed that Pradaxa 150 mg bid reduced the rate of stroke by 35% compared with well-controlled warfarin, irrespective of a patient's stroke risk Comparable to Lovenox in the prevention of major venous thromboembolism (VTE) and VTE-related mortality after both knee and hip replacement, according to RE-NOVATE data Equal efficacy to well-controlled warfarin in the treatment of acute VTE, but with a 37% reduction in major or clinically relevant bleeding risk over 6 months, according to RECOVER data |
2楼2013-04-03 10:38:46
13楼2013-04-09 19:00:34
★ ★ ★ ★ ★ ★
小木虫: 金币+0.5, 给个红包，谢谢回帖
williamxiang: 金币+5 2013-04-03 10:47:53
小木虫: 金币+0.5, 给个红包，谢谢回帖
williamxiang: 金币+5 2013-04-03 10:47:53
|
Weaknesses A superiority claim over warfarin in stroke prevention was rejected for inclusion in the label by the FDA A 110 mg doseage was not approved for use in patients at higher bleeding risk A higher risk of myocardial infarction was seen in RE-LY Twice daily dosing, compared with once daily for Xarelto Not approved in the US for VTE prevention post-surgery, unlike Xarelto which was approved in July 2011 Has faced some safety concerns, and the label was updated to mandate renal testing in high-risk patients Associated with a 6% rate of major gastrointestinal hemorrhage during each patient year on treatment Other gastrointestinal side effects, including dyspepsia, nausea and gastritis, are increased compared with warfarin (35% vs 24%) Current lack of antidote Very short half-life once removed from specially designed desiccant-containing packaging |
3楼2013-04-03 10:41:12
★
小木虫: 金币+0.5, 给个红包，谢谢回帖
小木虫: 金币+0.5, 给个红包，谢谢回帖
|
Opportunities Approval in AF opens up a blockbuster market, and Pradaxa could garner a greater share of the market in the near term due to its first mover advantage Pradaxa could be viewed as superior to Xarelto given Xarelto's lack of superiority to warfarin on an intent-to-treat basis seen in the ROCKET AF trial Despite the proven efficacy of warfarin in stroke prevention, it has a number of limitations, such as an increased risk of bleeding and the need for patient monitoring and dose adjustment, which has created an unmet need for safe and effective alternatives Approval in acute coronary syndrome (ACS); phase III trials in this setting began in December 2007 Development of competitor Eliquis in ACS was discontinued following high rates of bleeding in trials High cost and considerable copay required for Pradaxa may fade as insurers realize potential savings from increased avoidance of ischemic events and hospitalization AF is the most common sustained cardiac rhythm disturbance, and prevalence increases with age Up to 60% of cases of AF are caused by hypertension or coronary artery disease, which are increasing in prevalence in most Western societies ACS is the leading cause of death in the US and one of the most prevalent non-communicable diseases in the world |
4楼2013-04-03 10:53:35
★ ★ ★ ★
williamxiang: 金币+4 2013-04-03 13:01:31
williamxiang: 金币+4 2013-04-03 13:01:31
|
Threats Commercial threat from Eliquis; current phase III data appear to support a superiority claim over warfarin which would differentiate the product Increased competition in the oral anticoagulant category; the marketing battle between Pradaxa, Xarelto and Eliquis will be key In Japan, Lixiana is in development for stroke prevention in AF, and could present competition in this market following Pradaxa's launch in March 2011 The drug may not gain approval in ACS given concerns about bleeding If approved, use in ACS may be limited given the availability of new, more potent antiplatelet regimes, such as AstraZeneca's Brilinta, that improve outcomes with less increased bleeding Physicians may be reluctant to switch patients who are well controlled on warfarin to other treatment options Price: the significant price difference between Pradaxa and warfarin could present reimbursement issue Self administration of low-molecular-weight heparins out of hospital by patients with AF undergoing elective cardioversion is a promising approach that may result in cost savings Low-molecular-weight heparins, in particular enoxaparin which presents a generic and efficacious option for DVT treatment and prophylaxis following orthopedic surgery |
5楼2013-04-03 10:54:50
6楼2013-04-03 10:56:14
7楼2013-04-03 11:15:17
8楼2013-04-03 13:02:42
10楼2013-04-04 00:54:08
11楼2013-04-06 12:19:13
12楼2013-04-06 21:54:49
14楼2013-04-10 00:30:10
15楼2013-04-11 20:08:46
16楼2013-04-26 06:35:02
17楼2013-09-03 16:57:58
18楼2013-09-10 18:04:01